The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration
Open accessAbstract
PURPOSE: To evaluate the efficacy and safety of ranibizumab 0.5 mg treat-and-extend (T&E) versus monthly regimens in patients with neovascular age-related macular degeneration (nAMD) from the TReat and extEND (TREND) study. DESIGN: A 12-month phase 3b visual acuity (VA) assessor-masked, multicenter, randomized, interventional study. PARTICIPANTS: Six hundred fifty patients. METHODS: Treatment-naïve nAMD patients (age, ≥50 years) were randomized 1:1 to receive either a ranibizumab 0.5 mg T&E (n = 323) or monthly (n = 327) regimen. MAIN OUTCOMES MEASURES: The primary objective was to show noninferiority of ranibizumab 0.5 mg T&E versus monthly regimen, as assessed by the change in best-corrected VA (BCVA) from baseline to the end of the study. Secondary objectives included change in retinal central subfield thickness (CSFT) from baseline to the end of study, treatment exposure, and safety. RESULTS: Overall, 89.8% (T&E) and 90.2% (monthly) of patients completed the study. Patient demographic and baseline characteristics were well balanced between the 2 treatment groups. The T&E regimen was noninferior (P < 0.001) to the monthly regimen, with a least squares mean BCVA change from baseline of 6.2 versus 8.1 letters to the end of study, respectively. In both treatment groups, most BCVA improvements occurred during the first 6 months and were maintained until the end of the study. The mean change in CSFT from baseline to the end of study was -169.2 μm and -173.3 μm in the T&E and monthly groups, respectively. Fewer injections were required in patients receiving the T&E (8.7) versus monthly (11.1) regimen, with mean number of postbaseline visits of 8.9 and 11.2, respectively. Types and rates of adverse events were comparable between the treatment groups. CONCLUSIONS: Ranibizumab 0.5 mg administered according to a T&E regimen was statistically noninferior and clinically comparable with a monthly regimen in improving VA from baseline to the end of study. No new safety signals for ranibizumab were identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Causes and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Prevalence of age-related maculopathy in Australia
Mitchell, P., Smith, W., Attebo, K., & Wang, J. J. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30846-9 · Cited by 1,062
Lalwani, G. A., Rosenfeld, P. J., Fung, A. E., Dubovy, S. R., Michels, S., Feuer, W., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.01.024 · Cited by 880
Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration
Wong, T., Chakravarthy, U., Klein, R., Mitchell, P., Zlateva, G., Buggage, R., Fahrbach, K., Probst, C., & Sledge, I. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.008 · Cited by 601
Ho, A. C., Busbee, B. G., Regillo, C. D., Wieland, M. R., Van Everen, S. A., Li, Z., Rubio, R. G., & Lai, P. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.009 · Cited by 590
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub3 · Cited by 520
The Prevalence of Age-Related Macular Degeneration in Asians
Kawasaki, R., Yasuda, M., Song, S. J., Chen, S.-J., Jonas, J. B., Wang, J. J., Mitchell, P., & Wong, T. Y. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.10.007 · Cited by 438
Holz, F. G., Amoaku, W., Donate, J., Guymer, R. H., Kellner, U., Schlingemann, R. O., Weichselberger, A., & Staurenghi, G. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.019 · Cited by 413 · cited 1×
“However, in a real-world clinical setting, improvement and maintenance of these gains often is lower because of a reduced number of retreatments.(29) Data from uncontrolled, retrospective analyses have shown that the PRN regimen leading to fewer than 5 injections in the first year are insufficient to sustain VA improv…”
BackgroundBerg, K., Pedersen, T. R., Sandvik, L., & Bragadóttir, R. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.041 · Cited by 392
Schmidt-Erfurth, U., Eldem, B., Guymer, R., Korobelnik, J.-F., Schlingemann, R. O., Axer-Siegel, R., Wiedemann, P., Simader, C., Gekkieva, M., & Weichselberger, A. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.09.004 · Cited by 387
Incidence and progression rates of age-related maculopathy: the Rotterdam Study.
Klaver, C. C. W., Assink, J. J. M., van Leeuwen, R., Wolfs, R. C. W., Vingerling, J. R., Stijnen, T., Hofman, A., & de Jong, P. T. (2001) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 353
Wykoff, C. C., Croft, D. E., Brown, D. M., Wang, R., Payne, J. F., Clark, L., Abdelfattah, N. S., & Sadda, S. R. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.08.009 · Cited by 275
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration
Gupta, O. P., Shienbaum, G., Patel, A. H., Fecarotta, C., Kaiser, R. S., & Regillo, C. D. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.032 · Cited by 272
Ranibizumab According to Need: A Treatment for Age-related Macular Degeneration
Spaide, R. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.02.024 · Cited by 241
Arnold, J. J., Campain, A., Barthelmes, D., Simpson, J. M., Guymer, R. H., Hunyor, A. P., McAllister, I. L., Essex, R. W., Morlet, N., Gillies, M. C., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.02.009 · Cited by 181
INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDED
Oubraham, H., Cohen, S. Y., Samimi, S., Marotte, D., Bouzaher, I., Bonicel, P., Fajnkuchen, F., & Tadayoni, R. (2010) · Retina · doi:10.1097/iae.0b013e3181de5609 · Cited by 152
Cohen, S. Y., Dubois, L., Tadayoni, R., Fajnkuchen, F., Nghiem‐Buffet, S., Delahaye-Mazza, C., Guiberteau, B., & Quentel, G. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.04.001 · Cited by 136
Abedi, F., Wickremasinghe, S., Islam, A. F. M., Inglis, K. M., & Guymer, R. H. (2014) · Retina · doi:10.1097/iae.0000000000000134 · Cited by 126
Dadgostar, H., Ventura, A. A. C. M., Chung, J. Y., Sharma, S. K., & Kaiser, P. K. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.05.033 · Cited by 125
da Silva, R. M., Axer‐Siegel, R., Eldem, B., Guymer, R. H., Kirchhof, B., Papp, A., Seres, A., Gekkieva, M., Nieweg, A., & Pilz, S. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.026 · Cited by 89
Self-citationWolf, A., & Kampik, A. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-013-2562-6 · Cited by 87
Toalster, N., Russell, M. W., & Ng, P. (2013) · Retina · doi:10.1097/iae.0b013e3182831265 · Cited by 66
Gibson, M., Thomson, H., Banas, K., Lutje, V., McKee, M. J., Martin, S., Fenton, C., Bambra, C. L., & Bond, L. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009820.pub3 · Cited by 56
Gillies, M. C., Walton, R., Arnold, J., McAllister, I. L., Simpson, J. M., Hunyor, A. P., Guymer, R. H., Essex, R. W., Morlet, N., & Barthelmes, D. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.050 · Cited by 50
Gianniou, C., Dirani, A., Ferrini, W., Marchionno, L., Decugis, D., Deli, A., Ambresin, A., & Mantel, I. (2014) · Eye · doi:10.1038/eye.2014.258 · Cited by 44
Cachulo, M. L., Laíns, I., Lobo, C. L., Figueira, J., Ribeiro, L., Marques, J. P., Costa, J. C., Vieira, A., Rodrigues, J., Alves, D., et al. (2016) · Acta Ophthalmologica · doi:10.1111/aos.12950 · Cited by 41
Self-citationStewart, M. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4051079 · Cited by 34
Gianniou, C., Dirani, A., Ferrini, W., Marchionno, L., Decugis, D., Deli, A., Ambresin, A., & Mantel, I. (2015) · Eye · doi:10.1038/eye.2014.321 · Cited by 18
Chen, Y. N., Powell, A.-M., Mao, A., & Sheidow, T. (2015) · Retina · doi:10.1097/iae.0000000000000691 · Cited by 11
Ferreras, Y. W. A. (2014) · Journal of Clinical & Experimental Ophthalmology · doi:10.4172/2155-9570.1000324 · Cited by 8
Cited by
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931
Heier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00010-1 · Cited by 785
Self-citationArtificial intelligence in retina
Schmidt-Erfurth, U., Sadeghipour, A., Gerendas, B. S., Waldstein, S. M., & Bogunović, H. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.07.004 · Cited by 779
Guymer, R. H., Markey, C. M., McAllister, I. L., Gillies, M. C., Hunyor, A. P., Arnold, J. J., Chang, A., Syed, A., Broadhead, G., Pham, T., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.11.025 · Cited by 317
RETOUCH: The Retinal OCT Fluid Detection and Segmentation Benchmark and Challenge
Bogunovic, H., Venhuizen, F., Klimscha, S., Apostolopoulos, S., Bab-Hadiashar, A., Bagci, U., Beg, M. F., Bekalo, L., Chen, Q., Ciller, C., et al. (2019) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2019.2901398 · Cited by 273
Metadata
- Authors
- Silva, R., Berta, A., Larsen, M., Macfadden, W., Feller, C., & Monés, J.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 125
- Issue
- 1
- Pages
- 57-65
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2753708825
- Cited by
- 266
- References
- 36
- FWCI
- 22.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.